Breaking Finance News

TD Securities disclosed Jean Coutu Group (TSE:PJC.A), boosting its price target to $17.50 earlier today

Having a price of $20.31, Jean Coutu Group (TSE:PJC.A) traded 0.00% even on the day. The last stock close price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. PJC.A has recorded a 50-day moving average of $0.00 and a 200-day moving average of $0.00. 0 shares of PJC.A traded hands, down from an average trading volume of 0

Reporting a potential downside of -0.14%, TD Securities upped the price target of Jean Coutu Group (TSE:PJC.A) to $17.50

On Thursday September 29, 2016, Scotia Capital released a statement about Jean Coutu Group (TSE:PJC.A) upped the target price from $0.00 to $19.00 that suggested a downside of -0.05%.

Recent Performance Chart

Jean Coutu Group (TSE:PJC.A)

Jean Coutu Group has with a one year low of $0.00 and a one year high of $0.00 and has a total market value of $0.

Brief Synopsis About Jean Coutu Group (TSE:PJC.A)

The Jean Coutu Group (PJC) Inc. is a Canada-based company, which is engaged in franchising pharmacy chains. The Company operates through two segments: franchising and generic drugs. Within the franchising segment, the Company carries on the franchising activity under the banners of PJC Jean Coutu, PJC Clinique, PJC Jean Coutu Sante and PJC Jean Coutu Sante Beaute; operates approximately two distribution centers, and coordinates various other services for its franchisees. In the generic drugs segment, the Company owns Pro Doc Ltd, a Canadian manufacturer of generic drugs whose revenues come from the sale of generic drugs to wholesalers and pharmacists. The Company has approximately 420 PJC franchised stores in Quebec, Ontario and New Brunswick. The Company's services to its franchisees include centralized purchasing, distribution, marketing, training, human resources, management, operational consulting and information systems, as well as a private label program.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.